BofA raises Marsh stock price target to $179 on strong results

BofA lifted its price target on Marsh & McLennan to $179 from $174 while keeping an Underperform rating, after the company beat earnings estimates with Q1 adjusted EPS of $3.29 and revenue of $7.6 billion. Total revenue grew 8%, above BofA’s 4% estimate, and Marsh repurchased $750 million of stock versus the firm’s $400 million expectation. Management kept its 2026 capital deployment plan at $5 billion, spanning buybacks, dividends and M&A, though near-term repurchases will depend on M&A activity.

Analysis

MMC is still compounding, but the important tell is capital allocation, not the modest earnings beat. A larger-than-expected buyback in the quarter suggests management is willing to use excess cash aggressively when M&A pipelines are not compelling; that creates a near-term floor under EPS growth even if organic revenue cools. The key second-order effect is that a “below-guidance” M&A environment can actually improve shareholder returns faster than consensus models imply, because repurchases become the default use of capital.

The market may be underappreciating the tension between valuation and quality. A premium multiple on a defensive, fee-based financial compounder is justified only if buybacks and margin discipline keep offsetting slower top-line acceleration; if that cadence slips, the de-rating can be abrupt because the stock is already priced for durability. The risk is not an earnings miss next quarter, but a change in capital deployment mix over the next 2-3 quarters that forces investors to reassess the buyback runway.

Contrarianly, the stock’s relative weakness may be overstating the downside because the next leg of support likely comes from capital returns rather than operating momentum. If repurchases stay above plan and M&A remains muted through year-end, consensus EPS for the next 12 months could drift higher by low-single digits without much fanfare. Conversely, if deal activity accelerates, that could be strategically good long term but near-term negative for the stock because it reduces the most visible support for per-share growth.

Key Decisions for Investors

• Short-dated bullish trade: sell puts on MMC 1-2 earnings cycles out only if implied vol is elevated; target a modest premium capture with downside buffered by expected buyback support.
• Relative-value idea: long MMC / short a lower-quality insurance broker or diversified financial with less consistent capital returns over the next 1-3 months; thesis is MMC’s per-share compounding should outperform if buybacks remain above plan.
• If already long MMC, hedge a 2-3 month holding period with a collar rather than outright selling; the main risk is not fundamentals collapsing but multiple compression from valuation saturation.
• Watch for a pullback into the low-$170s to add; that would offer a better entry if the market overreacts to any M&A announcement that temporarily slows repurchases.